These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17965313)

  • 1. Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!
    Rosenstock J; Fonseca V
    Diabetes Care; 2007 Nov; 30(11):2972-3. PubMed ID: 17965313
    [No Abstract]   [Full Text] [Related]  

  • 2. [Exenatide--an alternative to insulin in the treatment of type 2 diabetes?].
    Kjeldsen R; Sandbaek A
    Ugeskr Laeger; 2008 Sep; 170(39):3039-43. PubMed ID: 18822227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide once weekly in type 2 diabetes.
    Scheen AJ
    Lancet; 2008 Oct; 372(9645):1197-8. PubMed ID: 18782642
    [No Abstract]   [Full Text] [Related]  

  • 4. Exenatide: excessive weight loss.
    Prescrire Int; 2011 Jan; 20(112):17. PubMed ID: 21462789
    [No Abstract]   [Full Text] [Related]  

  • 5. Exenatide in combination therapy: small study, big market, and many unanswered questions.
    Malozowski S
    Ann Intern Med; 2007 Apr; 146(7):527-8. PubMed ID: 17404355
    [No Abstract]   [Full Text] [Related]  

  • 6. Exenatide (Byetta) for type 2 diabetes.
    Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical application of exenatide in Japanese patients with type 2 diabetes mellitus].
    Toyonaga T; Araki E
    Nihon Rinsho; 2011 May; 69(5):890-4. PubMed ID: 21595277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exenatide and rare adverse events.
    Ahmad SR; Swann J
    N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920
    [No Abstract]   [Full Text] [Related]  

  • 9. Exenatide and acute pancreatitis.
    Tripathy NR; Basha S; Jain R; Shetty S; Ramachandran A
    J Assoc Physicians India; 2008 Dec; 56():987-8. PubMed ID: 19322980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 analogues for type 2 diabetes.
    Wilding JP; Hardy K
    BMJ; 2011 Feb; 342():d410. PubMed ID: 21325387
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment with new preparations against type 2 diabetes not sufficiently documented].
    Karlsson EA; Palmér M; Malmström R
    Lakartidningen; 2008 Feb 27-Mar 4; 105(9):647-8; author reply 648-9. PubMed ID: 18376713
    [No Abstract]   [Full Text] [Related]  

  • 12. Pancreatitis associated with incretin-based therapies.
    Iyer SN; Tanenberg RJ; Mendez CE; West RL; Drake AJ
    Diabetes Care; 2013 Apr; 36(4):e49. PubMed ID: 23520376
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of type 2 diabetes with new oral antihyperglycaemic drugs].
    Seissler J
    MMW Fortschr Med; 2008 May; 150(18):27-31. PubMed ID: 18533605
    [No Abstract]   [Full Text] [Related]  

  • 14. [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].
    Sjöholm A; Agardh CD; Brismar K; Efendic S; Eliasson B; Eriksson JW; Frid A; Groop L; Holmgren J; Ridderstråle M; Smith U
    Lakartidningen; 2008 Apr 23-May 6; 105(17-18):1310, 1312. PubMed ID: 18561535
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.
    Smits MM; Tonneijck L; Muskiet MH; Diamant M; Kramer MH; Cahen DL; van Raalte DH
    Diabet Med; 2017 Apr; 34(4):591-592. PubMed ID: 27278095
    [No Abstract]   [Full Text] [Related]  

  • 16. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
    Painter NA; Morello CM; Singh RF; McBane SE
    J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [GLP-1 agonists: an overview].
    Hinneburg I
    Med Monatsschr Pharm; 2013 Jul; 36(7):246-51. PubMed ID: 23898602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time for clinically relevant comparative effectiveness studies in type 2 diabetes.
    Nathan DM
    Ann Intern Med; 2011 Jan; 154(2):131-2. PubMed ID: 21135287
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide added to insulin. Beware the potentially serious adverse effects of exenatide.
    Prescrire Int; 2013 Jun; 22(139):151. PubMed ID: 23885352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.